
News|Articles|January 1, 2002
Acute migraine therapy: Triptan quantity limit maintains total health care savings 1 year out
Prime Therapeutics, St. Paul, MN-Do quantity limits on abortive migraine medications (ie, triptans) and educational efforts to increase the use of prophylactic therapy reduce total health care costs over the long term?
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Top 5 stories from Formulary Watch in 2025
2
Jascayd gets second FDA approval, this time for progressive pulmonary fibrosis
3
What NCCN’s next CMO sees ahead for cancer guidelines, access and innovation
4
5 developments in the treatment of prurgio nodularis in 2025
5





















































